Condition: Uveal Melanoma · Sponsor: IDEAYA Biosciences
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
This description comes directly from the study's public registry record.
IDEAYA Clinical Trials · +1-855-433-2246 · IDEAYAClinicalTrials@ideayabio.com
Mwe Mwe Chao, MD · mchao@ideayabio.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Scottsdale - PPDS | Scottsdale, Arizona, United States | Recruiting |
| UCSD Moores Cancer Center | La Jolla, California, United States | Not Yet Recruiting |
| Jules Stein Eye Institute | Los Angeles, California, United States | Not Yet Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Not Yet Recruiting |
| University of California Irvine Medical Center | Orange, California, United States | Not Yet Recruiting |
| Stanford Comprehensive Cancer Center | Palo Alto, California, United States | Recruiting |
| Kaiser Permanente-Riverside Medical Center | Riverside, California, United States | Recruiting |
| UCSF Wayne and Gladys Valley Center for Vision | San Francisco, California, United States | Not Yet Recruiting |
| University of Colorado Hospital | Aurora, Colorado, United States | Recruiting |
| The Melanoma and Skin Cancer Institute | Englewood, Colorado, United States | Not Yet Recruiting |
| Mayo Clinic Jacksonville | Jacksonville, Florida, United States | Recruiting |
| USF Health Eye Institute | Tampa, Florida, United States | Not Yet Recruiting |
+ 82 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07015190